Cgm Dexcom denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for cgm dexcom are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Issue a "Not FDA-Approved" Denial for Dexcom CGM

A "not FDA-approved" denial in this context almost always reflects an administrative mismatch rather than a factual statement about the device. Dexcom CGM systems carry FDA clearance or approval for continuous glucose monitoring; however, Humana may deny a specific claim if the submitted use does not align with the approved indication listed in the FDA labeling, if the device was billed under an incorrect code, or if Humana's internal policy restricts coverage to uses it has defined as within-label. Understanding the precise stated reason — which Humana is required to provide in writing — is the first step before appealing.

## Why This Denial Is Appealable

ACA §2719 requires non-grandfathered plans to offer internal appeals and access to independent external review. ERISA §503 requires full-and-fair review for employer plans. You have approximately 180 days from the denial notice to file an internal appeal and approximately four months from the final internal denial to request external review. Expedited review is available if delay would seriously jeopardize your health.

If the denial rests on a factual error — for example, if the claim was coded incorrectly — a corrected resubmission may resolve the issue without a formal appeal. If it reflects a policy disagreement about indicated use, the appeal process applies.

## The Appeal Process

1. Obtain the denial letter's specific rationale and the exact clinical criteria Humana applied. 2. Obtain the current FDA-approved prescribing information / labeling for the specific Dexcom device prescribed. This is publicly available on the FDA website and Dexcom's prescribing documentation. 3. Compare your prescribed use to the labeled indication. If your use is within the approved indication, document this explicitly. 4. File a Level 1 internal appeal attaching the FDA labeling, a prescriber letter confirming the prescribed use is within label, and your diagnosis documentation. 5. Escalate to external review if internal appeals are exhausted.

## Documentation to Gather

• FDA device labeling: The current prescribing information identifying approved indications for the specific Dexcom model.
• Prescriber letter: Confirmation that the prescribed use falls within the FDA-approved indication and an explanation of clinical necessity.
• Diagnosis documentation: Chart notes confirming the diagnosis that forms the basis of the prescription.
• Billing codes: Confirm with your provider that the correct HCPCS codes were submitted; a coding error can generate a not-approved denial that is resolved by resubmission.

## Criteria-Mapping Structure

Request Humana's coverage policy for CGM devices. For each policy criterion or restriction cited in the denial, document the specific clinical fact or labeling reference that answers it. Where Humana asserts a use is not within label, attach the relevant section of the FDA labeling and have your prescriber directly refute the assertion in the appeal letter.